Literature DB >> 9436964

Cellular kinetics in Barrett's epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation.

G Y Lauwers1, O Kandemir, P S Kubilis, G V Scott.   

Abstract

To gain insight into the neoplastic progression of Barrett's epithelium (BE), we assessed the expression of Ki-67 antigen and bcl-2 protein and the occurrence of apoptosis in metaplastic epithelium with and without regenerative atypia (RA), low-grade dysplasia, and high-grade dysplasia (HGD). To refine our understanding of the epithelial kinetics during the carcinogenic sequence, we performed separate analyses of four different mucosal regions, i.e., surface epithelium, upper and lower crypts, and glands. Expansion of the proliferative zone was noted in dysplasia and to a mild degree in epithelium with RA but not in BE. Expression of bcl-2 protein was seen in the proliferative zone in BE and showed a significant increase in RA but was essentially absent in HGD. Numerous apoptotic nuclei were seen in HGD, decreasing along the cellular gradient from gland to surface. We noted a positive correlation between Ki-67 and bcl-2 in the proliferative zone of BE and RA, whereas a negative correlation was present on the surface of RA. Ki-67 was positively correlated with apoptosis in the lower crypts of HGD. bcl-2 expression was negatively correlated with apoptosis in all regions except the proliferative zone of dysplastic areas. Our findings suggest that overexpression of bcl-2 protein is not an important step in the carcinogenesis of BE. We confirm the upward shift of cellular proliferation in dysplastic epithelia. Apoptosis that is increased in dysplasia might play a significant role in carcinogenesis by restraining increased cellular proliferation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9436964

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.

Authors:  Sumera Rizvi; Cathrine J Demars; Andrea Comba; Vladimir G Gainullin; Zaheer Rizvi; Luciana L Almada; Kenneth Wang; Gwen Lomberk; Martin E Fernández-Zapico; Navtej S Buttar
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

3.  Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.

Authors:  Minna Nortunen; Heikki Huhta; Olli Helminen; Seppo Parkkila; Joonas H Kauppila; Tuomo J Karttunen; Juha Saarnio
Journal:  Virchows Arch       Date:  2018-07-31       Impact factor: 4.064

4.  Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia.

Authors:  H A Saleh; H Jackson; G Khatib; M Banerjee
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

5.  Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa.

Authors:  J J Going; W N Keith; L Neilson; K Stoeber; R C Stuart; G H Williams
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 6.  Chemoprevention in Barrett's esophagus.

Authors:  Sumera Ilyas; Cathrine J DeMars; Navtej S Buttar
Journal:  J Gastrointest Cancer       Date:  2007

Review 7.  Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction.

Authors:  Nicholas J Clemons; Wayne A Phillips; Reginald V Lord
Journal:  Cancer Biol Ther       Date:  2013-06-17       Impact factor: 4.742

8.  Ki-67 Antigen Overexpression Is Associated with the Metaplasia-Adenocarcinoma Sequence in Barrett's Esophagus.

Authors:  Bernardo Silveira Volkweis; Richard Ricachenevsky Gurski; Luise Meurer; Guilherme Gonçalves Pretto; Guilherme da Silva Mazzini; Maria Isabel Edelweiss
Journal:  Gastroenterol Res Pract       Date:  2012-07-11       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.